Toviaz
Product Images NDC 69189-0244

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Toviaz (NDC 69189-0244). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avera Mckennan Hospital, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fesoterodine Er 8 mg Tablet (6918902441)

This is a description of a medication called Fesoterodine Fumarate ER, sold under the brand name Toviaz in the form of an 8mg tablet. The manufacturer of the medicine is Pfizer, and the lot number on the package reads as M25548. This medication has been assigned the NDC number 6918902441. The rest of the text seems to be related to the inventory management of the product, including its hospital lot number and expiration date.*

FDA Label Image

Chemical Structure (Toviaz 01)

FDA Label Image

Figure 1 (Toviaz 02)

The text describes the mean change from baseline in the number of micturitions per 24 hours in a study. It also presents a figure showing the change in the number of micturitions over 12 weeks for a group of patients who received a placebo and another group who received Toviazdmg.*

FDA Label Image

Figure 2 (Toviaz 03)

FDA Label Image

Figure 3 (Toviaz 04)

This appears to be a statistical result describing the mean change from baseline (in terms of the number of micturitions per 24 hours) in a study involving three groups: a placebo group (N=266), a group given Toviaz 4mg (N=267), and a group given Toviaz 8mg (N=267). The mean change from baseline for all groups combined was a decrease of 0.5 micturitions/day. Figure 3 illustrates the change in number of micturitions over time for each group.*

FDA Label Image

Figure 4 (Toviaz 05)

The text provides a figure (Figure 4) that shows the change in urge incontinence episodes per 24 hours over a 12-week period for three different groups of participants: placebo (N=205), Toviaz 4mg (N=228), and Toviaz 8mg (N=218). The horizontal axis represents the weeks of the study, while the vertical axis represents the change in the number of incontinence episodes per 24 hours. No further information is available.*

FDA Label Image

Logo (Toviaz 06)

This text appears to be a fragment of a company name and address which is not fully readable due to errors. Therefore, a useful description cannot be generated.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.